Jose Echeverz-Medina
Martinsried, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
NK cell-mediated tumor cell killing by bispecific innate cell engagers induces ADCC-mediated activation of primary human dendritic cells.
Journal: Oncoimmunology
Published: January 18, 2026
MVA-Spike encoding the A subunit of dmLT safely enhances systemic and mucosal immune responses.
Journal: Frontiers in immunology
Published: December 19, 2025
The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS.
Journal: Nature communications
Published: February 21, 2024
Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis.
Journal: Journal for immunotherapy of cancer
Published: October 12, 2023
Armored modified vaccinia Ankara in cancer immunotherapy.
Journal: International review of cell and molecular biology
Published: August 04, 2023
Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication.
Journal: Scientific reports
Published: August 12, 2022
Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis.
Journal: Oncoimmunology
Published: July 21, 2022
Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors.
Journal: Journal for immunotherapy of cancer
Published: June 27, 2021
Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications.
Journal: Cancers
Published: February 02, 2021
Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory.
Journal: Journal for immunotherapy of cancer
Published: December 22, 2020
CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation.
Journal: Nature communications
Published: October 13, 2020
Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies.
Journal: Nature communications
Published: December 06, 2018
Showing 1-12 of 12
Last Updated: 09/26/2026